Overview

Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression

Status:
Active, not recruiting

Trial end date:
2021-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this Phase 2, open-label, single-arm study is to determine the safety and the maximal tolerated dose (MTD) of VAL-083 in combination with a standard of care radiation regimen when used to treat newly diagnosed GBM in patients with unmethylated promoter of the methylguanine-DNA methyltransferase (uMGMT) gene. Pharmacokinetic (PK) properties will be explored and tumor responses to treatment will be evaluated.

Phase:

Phase 2

Details

Lead Sponsor:

DelMar Pharmaceuticals, Inc.
Kintara Therapeutics, Inc.

Collaborator:

Sun Yat-sen University

Treatments:

Dianhydrogalactitol